Baby Steps Aren't Enough

The saga of the prematurity-prevention drug Makena and the outrage over its pricing continues: on Friday, the maker of the drug, a subsidiary of KV Pharmaceutical, announced it would reduce its price 55%, from $1,500 to $690 per dose.

There is just one problem.  That is not enough.

This is a drug that was recently only ten dollars per dose. There is no explanation for this decision.  No sound need or reasoning has been given.  Don't want Obamacare?  Groovy, baby.  Protect the consumer and make sure drug companies don't do this.  And while you're at it, make sure health insurance companies can't do this.  Or this.  Or even though it's old news, this.